Arctic Bioscience - Q3 2022 Operational update – Positive progress in both pharma and nutra
Highlights Q3 2022: · HRO350 development on track with CTA submitted start of October 2022 · First patient expected to be enrolled in Q4 2022 · Record high deliveries of Nutra products to the Asian market during Q3 2022 · Total revenues almost doubled in Q3 2022 compared to Q3 2021, and YTD revenues has already surpassed full year revenues in 2021 · YTD revenues of NOK 23,9 million as of Q3 2022, compared to NOK 16,8 million as of Q3 2021 · Solid financial position with NOK 171,0 million in cash by 30. September 2022During Q3 2022 Arctic Bioscience had a positive